Abstract 227P
Background
Even though patients with non-muscle invasive urothelial carcinoma (NMIUC) show favorable survival rates, more than a half of them relapse during follow-up, while up to 20% progress to muscle-invasive urothelial carcinoma (MIUC). As the presence of invasion confers significant prognostic and therapeutic implications for these patients, its accurate detection is imperative; this has prompted the search for biomarkers predictive of invasion, using mostly genomic analysis. In contrast to the extensive genome-based research published so far in the field of BUC, studies utilizing in-depth proteomic analysis on patient-derived tissue samples, directed toward the identification of biomarkers predictive of tumor invasion, have barely been performed.
Methods
A total of 265 radical cystectomy specimens were selected from the Department of Pathology, Seoul National University Hospital (SNUH). This cohort consisted of 39 formalin-fixed paraffin embedded (FFPE) whole tissue samples used for the in-depth proteomics analysis, besides 226 BUC cases processed and analyzed as tissue microarrays (TMAs) to validate the in-depth proteomics findings along with in vitro testsFor proteomic analysis, 31 tissue specimens, consisting of 9 IUP, 12 PUC, and 10 normal urothelium (NU), were included. Machine learning-based feature selection for candidate markers For validation of IUP, we performed immunohistochemical staining in an independent valid. ation cohort composed of 25 IUP and 16 PUC with inverted growth.
Results
Validation of TUBB6 and TGFBI as potential predictive markers of muscle-invasive urothelial carcinoma (MIUC) and prognosis determinants. tubulin beta 6 class V (TUBB6) and TGFBI mRNA high expression and TUBB6 and TGFBI protein expression levels among NMIUC (pTa/pT1) and MIUC (pT2-pT4) (SNUH). From the overall proteomic landscape, The immunohistochemical validation PYGB as a specific biomarker to distinguish between IUP and PUC with inverted growth.
Conclusions
We propose TUBB6 as a novel IHC biomarker to predict invasion and poor prognosis, also select the optimal treatment in BUC patients. We suggest PYGB as a promising immunohistochemical marker for IUP diagnosis in routine practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract